Bionano Genomics Announces Extensive Lineup of Content to be Presented at the Annual Meeting of the Association for Molecular Pathology Featuring Optical Genome Mapping Across a Broad Range of Clinical Research Applications
November 15 2021 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) and provider of industry-leading data interpretation
solutions for next-generation sequencing (NGS) and microarrays,
today announced the lineup of content scheduled to be presented at
the annual meeting of the Association for Molecular Pathology
(AMP). The content is expected to include an oral platform
presentation by Dr. Ravi Kolhe at Augusta Universty, six poster
presentations, a corporate workshop and an innovation spotlight.
The presentations this year span a wide range of applications,
including prenatal analysis, genetic disease, hematological
malignancies, solid tumor and advances in the OGM technique for
detecting more clinically relevant variants, including absence of
heterozygosity (AOH) and allelic imbalance. The AMP conference is
being held virtually starting today, Monday, November 15 and goes
until Friday, November 19, 2021.
Bionano’s corporate workshop on Thursday, November 18 from
9:00am - 9:50am EST is planned to feature presentations from Dan
Saul (BioDiscovery), Dr. Alex Hastie (Bionano), and Dr. Gordana
Raca (Children’s Hospital LA), where they’ll highlight the
potential advantages of combining data from OGM and next-generation
sequencing (NGS) to obtain the most comprehensive view of genome
variation available.
The innovation spotlight will feature presentations from Dr.
Soheil Shams (CIO), Dr. Alka Chaubey (CMO) and Dr. Adrian Dubuc
from Brigham & Women’s Hospital and Harvard Medical School. The
content for the spotlight will cover Bionano’s efforts in building
a cancer knowledgebase for interpreting variants faster, the power
of combining OGM and NGS data to reveal significantly more
clinically relevant variants than with NGS alone and an
illustration of an application of OGM as an alternative to
karyotyping and FISH for revealing complex, clinically relevant
structural variants in an aggressive leukemia/lymphoma subject.
The table below outlines each presentation together with the
program number for ease of location during the event.
OGM Application Area |
Presentation / Poster Title |
Affiliation |
Genetics |
G22. Comprehensive Evaluation and Validation of Amniocytes Using
Optical Genome Mapping: From Sample Preparation to Reporting |
Augusta University |
Hematopathology |
H02. Clinical Validation of Optical Genome Mapping to Replace
Eosinophilic Leukemia FISH Panel |
University Health Network, Toronto, Canada |
H13. Comprehensive Detection of Structural Somatic Mutation in
Hematological Cancers by Optical Genome Mapping |
Bionano Genomics |
H15. Clinical Utility of Optical Genome Mapping in Cytogenetic
Analysis of Hematologic Malignancies |
Augusta University |
Informatics |
I12. Detecting Absence of Heterozygosity Using High-Resolution
Optical Genome Mapping |
Bionano Genomics |
Solid Tumors |
ST74. Optical Genome Mapping for the Chromosomal Characterization
of Solid Tumors |
Augusta University |
Technical Topics |
TT24. Optical Genome Mapping: Optimizing Sample Types for Prenatal
Testing, Constitutional Disorders, Hematological Malignancies, and
Solid Tumor Profiling |
Augusta University |
Workshop |
Topic |
Date and Time |
Corporate Workshop |
Combining Optical Genome Mapping (OGM) with Next-Generation
Sequencing (NGS) Data to Provide the Most Comprehensive Genome
Analysis for Oncology Applications |
Thursday, November 18th from 9:00am - 9:50am EST |
“We are thrilled to see the broad range of presentations
featuring OGM at AMP this year, including coverage of the
combination of OGM with NGS data to provide the most comprehensive
picture of the genome,” stated Erik Holmlin, PhD, CEO of Bionano
Genomics. “Our customers continue to push forward cutting-edge
applications in molecular pathology and we look forward to the
authors sharing their research with the AMP community.”
For more details and to register for this online event please go
to: https://amp21.amp.org/
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through optical genome
mapping (OGM) solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the timing and content
of the posters and presentations regarding OGM to be presented at
the AMP conference; and the effectiveness and utility of OGM,
including in combination with NGS and in comparison to traditional
standard of care methods. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
accuracy of customer posters and presentations to be presented;
observations from studies covered by the posters and presentations
may not be replicated; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2020 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024